Innoforce, a biopharmaceutical innovation enabling platform and Partner Development and Manufacturing Organisation, has signed a contract with dMed, a clinical CRO with a strong presence in China and the United States, to establish a collaboration to identify, evaluate, and collaborate on the development of clinical-stage therapeutics, it was reported on Tuesday.

Both firms are to concentrate on advancing access to the new drugs for Chinese patients in addition to improving pharmaceutical manufacturing and development opportunities globally. The firms associated with the Innoforce and dMed partnership will be accommodated on the Innoforce campus in Hangzhou.

Dr Yuling Li, the Innoforce CEO, said, 'Innovative biologic drugs, as well as cell and gene therapies, are the future drivers of biomedicine. The unique PDMO (partner development manufacturing organisation) model that Innoforce is pioneering based on global quality manufacturing capabilities combined with our collaboration with dMed will bring the highest global standards to our partners' cutting-edge pharmaceutical research and development for China and the World.'